Discovery Of Ant3310, A Novel Broad-Spectrum Serine Beta-Lactamase Inhibitor Of The Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity Against Carbapenem-Resistant Enterobacterales And Acinetobacter Baumannii
JOURNAL OF MEDICINAL CHEMISTRY(2020)
摘要
The diazabicyclooctanes (DBOs) are a class of serine beta-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as several other recently approved DBOs (e.g., relebactam) or those in clinical development (e.g., nacubactam and zidebactam) potentiate activity of beta-lactam antibiotics, to various extents, against carbapenem-resistant Enterobacterales (CRE) carrying class A, C, and D SBLs; however, none of these are able to rescue the activity of beta-lactam antibiotics against carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO "critical priority pathogen" producing class D OXA-type SBLs. Herein, we describe the chemical optimization and resulting structure-activity relationship, leading to the discovery of a novel DBO, ANT3310, which uniquely has a fluorine atom replacing the carboxamide and stands apart from the current DBOs in restoring carbapenem activity against OXA-CRAB as well as SBL-carrying CRE pathogens.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络